Partnership and collaboration allow us to realize the potential of psychedelic therapy in our mission to support patients in healing. We believe working together in strong, committed partnerships is essential to bring about a paradigm shift this significant.
Partner with Sunstone

Medical Partnership

Adventist HealthCare

Our first partnership is with Adventist Healthcare and their standalone Aquilino Cancer Center. Sunstone leadership helped design and continues to power the Bill Richards Center for Healing, the site of Sunstone’s first clinical trial.

Pharmaceutical Partners


Beckley Psytech

Beckley’s innovative approach to helping patients in need is focused on developing novel psychedelic therapies to improve patient outcomes. Sunstone is currently participating as a clinical site for Beckley’s Intranasal BPL-003 (5-MeO-DMT) for Treatment-Resistant Depression (TRD) study; Sunstone has also hosted training for Beckley at our center.

COMPASS Pathways

Compass is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Sunstone has worked with COMPASS since our first psilocybin study launched in November 2020. We currently are participating as a site for their COMP104 study, a Phase 2, randomized, double-blind, controlled study to investigate psilocybin in participants with Major Depressive Disorder; additionally, therapists from other sites for this study come to Sunstone’s center for training. Sunstone participated as a site for Compass’ COMP201 study, an open-label study to investigate psilocybin in participants with post-traumatic stress disorder.

Lykos Therapeutics (MAPS)

Lykos Therapeutics, previously the Multidisciplinary Association of Psychedelics, develops medical, legal, and cultural shifts so people can benefit from the careful use of psychedelics and marijuana for mental health, well-being, and connection. Sunstone is a site for Lykos Therapeutics’ Expanded Access study; Sunstone also serves as a site for EA therapists to complete the supervision portion of their training. Sunstone is also conducting our own IIT study (IUSAD1/Dyad) using Lykos’ MDMA to explore adjustment disorder in dyads of patients with cancer and a concerned significant other.


MindMed works to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in the fields of psychiatry, addiction, pain, and neurology. Sunstone participated as a clinical site for MindMed’s Lysergic Acid Diethylamide Phase II for Generalized Anxiety Disorder (GAD) study.

Usona Institute

Usona Institute continues the exploration and learning around consciousness-expanding medicines to address some of society’s most challenging mental health conditions. Usona provides Sunstone with psilocybin and Niacin for our new group cancer study (2 psilocybin).

Reunion Neuroscience

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. Sunstone is helping Reunion to plan for an oncology indication with psychedelics.

Academic Partners

Dana-Farber Cancer Institute

Sunstone collaborates with the Dana-Farber Cancer Institute to develop and publish clinical studies. Dr. Yvan Beaussant, a national expert in palliative care and a pioneer researcher in psychedelic-assisted therapy, serves on the faculty of the Dana-Farber Cancer Institute.

Learn More

Sunstone collaborated with Dr. Beaussant on the ACCEPT study, which was designed to glean treatment experience insights from psilocybin study participants. Sunstone helped design, fund, and enroll patients for this study. Sunstone is currently collaborating with Dr. Beaussant to investigate how MDMA-assisted therapy may benefit cancer patients and caregivers in dyadic treatment, and to understand the barriers that therapists in the BIPOC community face in entry to psychedelic therapy training.

Johns Hopkins Center for Psychedelic & Consciousness Research

Johns Hopkins Center for Psychedelic & Consciousness Research and Sunstone collaborate to support a postdoctoral fellow working with Sunstone at the Bill Richards Center for Healing, with a focus on studying psychedelics in cancer patients.

Learn More

Our post-doctoral candidate has written a paper on grief and adverse events, is working on a protocol to explore psychedelics and prolonged grief disorder, and plans to explore the potential use of functional neuroimaging in clinical studies.

The University of Vermont

Sunstone collaborated with Dr. Robert Gramling and his language lab to better understand the psychedelic experience for Sunstone patients, exploring the use of Natural Language Processing on audio and video recordings to measure therapeutic alliance.

Learn More

Dr. Gramling is an expert in palliative care and hospice, with over 70 articles published. He currently serves as the Inaugural Holly and Bob Miller Chair in Palliative Medicine and the Inaugural Chief of the Division of Palliative Medicine in the Department of Family Medicine at the University of Vermont Medical Center. 

McGill University

Sunstone Therapies advised McGill University to develop a grant with the Canadian Institutes of Health Research for a study to assess the efficacy, safety, and acceptability of group and individual psilocybin-assisted psychotherapy in end-of-life psychological distress. Sunstone Therapies informed the clinical trial protocol development in collaboration with McGill University.

National Institute of Health (NIH)

Dr. Ann Berger serves as Chief of Pain and Palliative Care at NIH’s research hospital. She recently developed the new innovative NIH-HEALS, which measures psychosocial spiritual healing of individuals with life-threatening and life-challenging situations. Sunstone worked with Dr. Berger to assess the utility of the NIH-HEALS in psychedelic therapy.

Memorial Sloan Kettering Cancer Center

Sunstone collaborated with the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center on a study of cancer patients using psychedelics in conjunction with meaning-centered therapy—designed to diminish feelings of despair associated with cancer and reconnect to life’s meaning in the face of illness. The manuscript from this study is being prepared for publication.


Fellows play a pivotal role in our journey, contributing their expertise in research, business, therapy, and medical domains. While we are not actively seeking new Fellows at this time, we invite you to meet our current partners who are driving innovation and excellence in our care and research initiatives.
Rebecca Ehrenkranz, Ph.D., MPH
Research Fellow
Shelby Muhammedi, L.C.S.W.
Therapy Fellow
Christina Kappil
M.B.A. Business Fellow

Partner with Us

We are open to partnering with institutions that share a passion for expanding the accessibility and delivery of psychedelic-assisted therapy.

Partner with Sunstone